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Abstract
Among the various pharmacological options to 
decrease peri-operative bleeding, tranexamic acid 
appears to be one of the most interesting. Several trials 
have consistently documented the efficacy of this 
synthetic drug in reducing the risk of blood loss and 
the need for allogeneic blood transfusion in patients 
undergoing total hip and knee arthroplasty. The safety 
of intravenous tranexamic acid in major orthopaedic 
surgery, particularly regarding the risk of venous 
thromboembolism, was systematically analysed in this 
review. A systematic search of the literature identified 
73 randomised controlled trials involving 4,174 patients 
and 2,779 controls. The raw overall incidence of venous 
thromboembolism was 2.1% in patients who received 
intravenous tranexamic acid and 2.0% in controls. A 
meta-analytic pooling showed that the risk of venous 
thromboembolism in tranexamic acid-treated patients 
was not significantly different from that of controls 
(risk difference: 0.01%, 95% confidence interval [CI]: 
−0.05%, 0.07%; risk ratio: 1.067, 95% CI: 0.760-1.496). 
Other severe drug-related adverse events occurred very 
rarely (0.1%). In conclusion, the results of this systematic 
review and meta-analysis show that intravenous 
tranexamic acid is a safe pharmacological treatment 
to reduce blood loss and transfusion requirements in 
patients undergoing major orthopaedic surgery.
Keywords: tranexamic acid, orthopaedic surgery, safety, 
thromboembolic events.
Introduction
Tranexamic acid (TXA) is a synthetic amino acid 
which competitively blocks the lysine binding sites 
on plasminogen, thereby slowing the conversion of 
plasminogen to plasmin1,2. Thanks to its ability to inhibit 
fibrinolysis and clot degradation, TXA, which can be 
administered intravenously, orally or topically, has been 
successfully used to prevent or decrease blood loss in a 
variety of clinical conditions characterised by excessive 
bleeding in patients with or without inherited bleeding 
disorders3,4. For instance, the early administration of 
TXA has been found to confer a survival benefit in 
the settings of severe trauma5,6 and of post-partum 
haemorrhage without an increase in thromboembolic 
events7. In addition, this haemostatic agent has been 
used successfully to decrease blood loss in numerous 
surgical specialties, particularly cardiac surgery8,9. More 
recently, TXA has been widely administered to minimise 
bleeding and exposure to allogeneic blood transfusion in 
major orthopaedic surgery and several large randomised 
clinical trials and meta-analyses have consistently 
confirmed that the intravenous administration of TXA 
could effectively and safely reduce perioperative blood 
loss and transfusion requirements in total hip and 
knee arthroplasty10-14. In spite of this sound evidence, 
however, some concerns still remain among physicians 
over the hypothetical increased risk of thromboembolic 
complications (i.e., venous thromboembolism [VTE], 
including deep vein thrombosis and pulmonary embolism) 
following the systemic infusion of this anti-fibrinolytic 
agent in the setting of orthopaedic surgery. Thus, to 
refute this unjustified, non-evidence-based perception, 
we conducted a systematic review and meta-analysis 
aimed at assessing the safety of intravenous TXA in 
patients undergoing major orthopaedic surgery.
Materials and methods
This systematic review was conducted according to 
the recommended PRISMA checklist guidelines15.
Search methods
A computer-assisted literature search of the Medline, 
Embase and Scopus electronic databases was performed 
to identify randomised clinical trials on the use of 
intravenous TXA in major orthopaedic surgery. The 
following search strategy was used to maximise the 
search specificity and sensitivity: "total knee arthroplasty 
OR total knee replacement OR total hip arthroplasty OR 
total hip replacement OR total shoulder arthroplasty 
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OR total shoulder replacement OR major orthopaedic 
surgery OR hip fracture surgery" and "tranexamic acid". 
In addition, we hand-searched the reference lists of the 
most relevant items (original studies and reviews) in 
order to identify potentially eligible studies not captured 
by the initial literature search.
Study selection
Study selection was performed independently by two 
reviewers (MF and CM), with disagreements resolved 
through discussion and on the basis of the opinion of 
a third reviewer (GML). The eligibility assessment 
was based on the title or abstract and on the full text if 
required. Articles were eligible if they reported either in 
the title or in in the abstract the use of intravenous TXA 
in patients undergoing major orthopaedic surgery. Studies 
on the use of TXA given by other routes of administration 
(i.e., oral or topical) were considered for the analysis only 
if they included an arm using intravenous TXA. Only 
randomised clinical trials published in full in English 
between January 1990 and July 2017 were included in 
this systematic review and meta-analysis16-88. 
Data extraction
For each study included in the systematic review, the 
following data were extracted by two reviewers (MF and 
CM) independently: study design, type of intervention, 
sample size (TXA and control groups), protocol (dose 
administered of intravenous TXA), thromboprophylaxis 
and TXA-related adverse events (i.e., VTE and other 
drug-related severe adverse events). The follow-up 
period for each trial was also recorded, when available.
Outcome measures
According to the study design of the different trials, 
the primary outcome measured was the safety TXA 
administered intravenously in major orthopaedic surgical 
procedures. The safety included mainly the incidence of 
venous thromboembolic complications (i.e., pulmonary 
embolism and deep vein thrombosis) following the 
intravenous administration of the anti-fibrinolytic agent. 
All the other drug-related severe adverse events were, 
however, also recorded. 
Statistical evaluation and meta-analysis
In each study, the risk of VTE was evaluated as risk 
difference (RD) and risk ratio (RR) between a group of 
TXA-treated patients and a group of control patients. 
The meta-analysis was done, as usual, by pooling these 
effect indexes. A fixed effect, inverse variance pooling 
of the RD was performed. This index enables the 
calculation of an important pharmaco-economic index, 
the number needed to treat in order to avoid an event. 
The heterogeneity χ2 was also calculated, as the I2 for the 
variation of RD due to heterogeneity. The same approach 
was used for the RR. 
Since many of the studies provide zero-events, the 
estimate of the pooled RD is less biased than that of the 
pooled RR, although it is not very accurate. Indeed, even 
the RD method cannot avoid recourse to correction for 
lack of continuity, to adjust for zero. Moreover, some 
authors view the use of the RD unfavourably, since this 
method yields wide confidence intervals when events 
are rare, with poor statistical power89,90. A method 
recently developed by Tian and colleagues91 for the RD, 
suitable for rare-event meta-analysis, appears appealing. 
It performs exact fixed effect meta-analysis for rare-
events data without the need for an artificial continuity 
correction. This procedure combines the confidence 
intervals for the RD obtained from all studies. For the 
classical RD and RR we used Stata v15.0 (StataCorp 
LLC, College Station, TX, USA), whereas for Tian's 
RD we used the R package "exactmeta" (https://cran.r-
project.org/web/packages/exactmeta/index.html). 
Results
Literature search and study characteristics 
In total, 824 articles were identified from the initial 
electronic and manual search, which was concluded 
on 7 September 2017 (Figure 1). Of these, 572 were 
excluded because they focused on other topics. Thus, 
244 potentially relevant articles were selected; the next 
screening led to the exclusion of 171 additional studies 
(case-reports, reviews, protocols of randomised clinical 
trials, duplicates, studies containing no informative 
data). The remaining 73 randomised studies16-88 
Figure 1 - Flow chart of the inclusion of the studies. 
 RCTs: randomised controlled trials.
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were included in the systematic review (see Online 
Supplementary Table SI for the main characteristics 
and results of the included studies), while six 
further studies57,73,76,78,80,86 were excluded from meta-
analytical pooling because they were uncontrolled. 
Overall, 4,174 patients who received intravenous 
TXA and 2,779 controls who received no treatment 
were enrolled in the 73 studies evaluated. With regards 
to the type of major surgery, 46 studies16-18, 20-22,24,25,27,33-
35,38,39,42,43,45-49,51-53,56-62,66-70,73-78,84-87 (2,960 cases and 1,924 
controls) were focused on total hip arthroplasty, 20 stu
dies19,23,26,28-32,37,41,44,50,55,63,64,71,79,80,82,83 (924 cases and 564 
controls) on total knee arthroplasty, six studies36,40,54,65,72,81 
(237 cases and 242 controls) on hip fracture surgery 
and one study88 (53 cases and 49 controls) on shoulder 
arthroplasty. The dosing and timing of intravenous TXA 
varied from study to study. However, in the majority of 
cases (45/73 studies, 61.6%) it was given before or during 
and after surgery at a bolus dose ranging between 10 and 
20 mg/kg. In 12 of the 73 studies (16.4%) TXA was also 
administered as a continuous intravenous infusion during 
surgery and/or postoperatively at a dose ranging between 
1 and 10 mg/kg/hour. Sixty-four of the 73 (87.7%) 
selected trials also reported informative data on the 
administration of thromboprophylaxis. In the majority 
of the studies (50/64, 78.1%), thromboprophylaxis 
consisted of low molecular weight heparin given at 
various dosages (see Online Supplementary Table SI) 
and for a period ranging between 5 days and 6 weeks 
postoperatively. In six studies, low molecular weight 
heparin was followed by the direct oral anticoagulant 
rivaroxaban administered at a dose of 10 mg/day. In 
seven other studies rivaroxaban was given alone at 
the same daily dose for 7-14 days post-operatively. 
Only one study used unfractionated heparin, while 
thromboprophylaxis with warfarin or aspirin alone 
was performed in one and three studies, respectively. 
In two other studies only mechanical antithrombotic 
prophylaxis was provided. 
Outcome analysis
The primary outcome analysed was the incidence of 
VTE. The VTE screening method performed was reported 
in 67/73 (91.8%) studies. In the majority of the cases 
(40/67 studies, 59.7%) VTE screening was based only on 
clinical examination (presence of symptoms and signs of 
thromboembolism), while in 24 additional studies (35.8%) 
an investigation with ultrasound or venography was also 
routinely associated. An additional laboratory screening for 
VTE (measurement of D-dimer levels) was also performed 
in four studies. The post-operative follow-up period ranged 
between three days and three months.
The overall incidence of VTE was 86 in 4,174 
(2.1%) patients who received intravenous TXA and 55 
in 2,779 (2.0%) control patients. A raw RD of 0.0008 
and a raw RR of 1.0411 could thus be calculated. 
Excluding the six uncontrolled studies, the incidence 
of VTE was 77 in 3,417 TXA patients (2.2%), and the 
related raw indexes were RD=0.0027 and RR=1.1386. 
With regards to the type of VTE, six (6/86, 
7.0%) patients in the TXA group and five (5/55, 
9.1%) patients in the control group had a pulmonary 
embolism, while the remaining patients (80/86 
[93.0%] in the TXA group and 50/55 [91.9%] in the 
control group) experienced deep vein thrombosis. 
The pooled meta-analytical RD was 0.001 (95% 
CI: −0.005 to 0.007). No heterogeneity was found, 
with an I2=0.0%. The statistical significance of the test 
of RD=0 was p=0.745, so the evidence against the null 
hypothesis of no difference between the two groups was 
very modest (Figure 2A). The number needed to treat 
was 1,000. The calculation of the RR was disturbed by 
many zero-event studies, which could not be evaluated. 
The pooled meta-analytical RR was 1.067 (95% CI: 
0.760 to 1.496). No heterogeneity was found, with 
an I2=0.0%. The statistical significance of RR=1 was 
p=0.708 (Figure 2B). Tian's RD was 0 (95% CI: −0.007, 
0.009), with a p=1.
Other severe adverse events possibly related to the 
administration of TXA occurred so rarely (5/3, 396, 
0.1%) that a statistical analysis could not be performed.
Discussion
Major orthopaedic surgical procedures, in particular 
total hip and knee arthroplasties, are continuously 
increasing worldwide due to population aging. For 
instance, in the USA alone, nearly 1,000,000 total 
knee and hip arthroplasties are performed each year92. 
Despite advances in surgical techniques, intra- and 
post-operative blood loss remains one of the most 
common and important complications associated 
with such operations, exposing patients to increased 
impairment of functional ability, longer stays in hospital 
and, ultimately, increased morbidity and mortality93. 
Allogeneic blood transfusion, a life-saving procedure 
used to correct post-operative anaemia, can, albeit 
rarely, be associated with serious adverse events94. In 
this context, a restrictive red blood cell transfusion 
strategy95,96 and the implementation of a patient blood 
management programme(PBM)97-101 in order to correct 
pre-operative anaemia have become the mainstay of 
management of patients undergoing major orthopaedic 
surgery. With regards to the latter issue, one of the 
most interesting methods of decreasing peri-operative 
blood loss and reducing the need for post-operative 
transfusion is based on the use of TXA and several 
hundreds of trials have assessed the potential beneficial 
effect of this pharmacological agent given topically and/
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or intravenously102,103. While the benefit of intravenous 
TXA in significantly reducing the risk of post-operative 
blood loss and the need for allogeneic blood transfusion 
has been demonstrated consistently by several systematic 
reviews and meta-analyses11,14,104,105, some concerns 
remain still among orthopaedic surgeons regarding its 
safety, in particular the risk of VTE. Thus, in order to 
contribute to a definitive response to these important 
concerns, we performed a systematic review and meta-
Figure 2A - Effect of tranexamic acid on VTE risk: meta-analytical pooling. Continued on next page.
 The effect was comparatively measured as risk difference (Figure 2A) and risk ratio (Figure 
2B). Squares denote the risk difference and risk ratio, with their size being proportional to the 
weight assigned to the study. Horizontal bars indicate the 95% CI for each study. The diamonds 
represent the aggregate effect, with their width representing the 95% CI of the total effect.
 CI: confidence interval; RD: risk difference; TXA: tranexamic acid; VTE: venous thromboembolism.
A
analysis focused on the safety of intravenous TXA in 
major orthopaedic surgery, particularly regarding its 
association with VTE risk.
After a systematic electronic and manual search, we 
identified 73 randomised clinical trials including almost 
7,000 patients. Such a large number of studies and 
patients enrolled, much larger than any other systematic 
review or meta-analysis previously published, is due 
to the pooling of all the randomised clinical trials 
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evaluating the intravenous administration of TXA in 
the setting of any type of major orthopaedic surgery 
(i.e., total hip, knee and shoulder arthroplasties and hip 
fracture surgery). 
After meta-analysis, we found that the risk of VTE, 
measured as RD and RR, in patients who received 
intravenous TXA was not significantly different from 
that in untreated controls. The negligible effect size 
of TXA on thromboembolic adverse events was also 
confirmed using the Tian's RD (which was zero), 
a statistical method developed to overcome the 
limitations due to rare events (such as the thrombotic 
events recorded in this meta-analysis). In addition, no 
significant difference in the distribution of the different 
types of VTE (i.e., pulmonary embolism and deep vein 
thrombosis) was recorded in both cases and controls.
While the large number of studies evaluated 
represents the main strength of our systematic review, it 
B
Figure 2B - Effect of tranexamic acid on VTE risk: meta-analytical pooling. Continued from previous page.
 The effect was comparatively measured as risk difference (Figure 2A) and risk ratio (Figure 
2B). Squares denote the risk difference and risk ratio, with their size being proportional to the 
weight assigned to the study. Horizontal bars indicate the 95% CI for each study. The diamonds 
represent the aggregate effect, with their width representing the 95% CI of the total effect.
 CI: confidence interval; RR: risk ratio; TXA: tranexamic acid; VTE: venous thromboembolism.
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must be pointed out that a significant proportion of these 
randomised clinical trials differed from each other with 
regards to study design and, in particular, TXA dosing 
and timing of administration. In addition, different 
antithrombotic prophylaxis regimens and VTE screening 
methods were applied in the various studies. Moreover, 
the baseline risk of thromboembolic events varies 
considerably depending on whether major orthopaedic 
surgery is performed on the upper or lower limbs.
All these variables could have influenced the 
occurrence and detection of VTE. Nevertheless, in spite 
of such limitations, no heterogeneity in the randomised 
clinical trials was detected by the I2 index (0%), which 
further validates the results of our study. 
In conclusion, this systematic review and meta-
analysis demonstrates the safety of the intravenous 
administration of TXA in patients undergoing major 
orthopaedic surgery. Our results, together with those 
from other previously published meta-analyses which 
document the efficacy of TXA and support the beneficial 
effect of this agent, TXA should, therefore, be used in 
orthopaedic surgery in the frame of PBM programmes.
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